Sonus Pharmaceuticals has announced a restructuring plan as part of its recent decision to focus on the development of its drug delivery and blood substitute products. The Bothell, WA-based firm will lay off 25% of its personnel, trimming staff to a core group of 30 people, according to the firm.
The cost of the restructuring in the company's fourth quarter will be approximately $300,000 for severance and related benefit payments, according to the company. Last week Sonus announced that it has withdrawn its EchoGen ultrasound contrast agent from the Food and Drug Administration approval process.
By AuntMinnie.com staff writersOctober 20, 2000
Related Reading
Sonus shocks market by withdrawing EchoGen ultrasound contrast application, October 13, 2000
Copyright © 2000 AuntMinnie.com